{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:41:20Z","timestamp":1793500880433,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and reporting of MG clinical trials. Recognizing that changes in clinical trial design and implementation may increase the likelihood that new therapies are developed for MG, the MGFA MSAB Task Force here presents updated recommendations for the design and implementation of clinical trials in MG, including (a) the use of a quantitative measure, such as the MG\u2010Composite, that is weighted for clinical significance and incorporates patient reported outcomes; (b) consideration of nontrial strategies; and (c) development of biomarkers that support mechanistic studies of pharmacotherapies. The hope is that these updated task force recommendations will expedite the development and acceptance of more effective and less noxious therapies for MG. Muscle Nerve 45: 909\u2013917, 2012<\/jats:p>","DOI":"10.1002\/mus.23330","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T16:26:49Z","timestamp":1327940809000},"page":"909-917","source":"Crossref","is-referenced-by-count":149,"title":["Recommendations for myasthenia gravis clinical trials"],"prefix":"10.1002","volume":"45","author":[{"given":"Michael","family":"Benatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Baggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Meriggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"THE TASK FORCE ON MG STUDY DESIGN OF THE MEDICAL SCIENTIFIC ADVISORY BOARD OF THE MYASTHENIA GRAVIS FOUNDATION OF AMERICA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.11.1157"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161205"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_2_12_9_2","volume-title":"ClinicalTrials.gov [Internet]","author":"Barohn RJ"},{"key":"e_1_2_12_10_2","volume-title":"ClinicalTrials.gov [Internet]","author":"Alexion Pharmaceuticals"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.031"},{"key":"e_1_2_12_12_2","volume-title":"ClinicalTrials.gov [Internet]","author":"Benatar M"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10224"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.11.1689"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2001.06717.x"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.031"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.057"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1034"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21016"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21185"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314245"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21713"},{"key":"e_1_2_12_31_2","unstructured":"US Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medicinal products. In: FDA.gov\/ScienceResearch\/SpecialTopics\/CriticalPath Initiative\/CriticalPathOpportunitiesReports\/ucm077262.htm. [Internet] [Accessed2011Apr 20]."},{"key":"e_1_2_12_32_2","unstructured":"US Food and Drug Administration. Innovation or stagnation: critical path opportunities list. In: FDA.gov\/ScienceResearch\/SpecialTopics\/ CriticalPathInitiative\/CriticalPathOpportunitiesReports\/default.htm. [Internet] [Accessed2011Apr 20]."},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4807"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043980"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000223353.34006.54"},{"key":"e_1_2_12_38_2","unstructured":"TACT:the TREAT\u2010NMD Advisory Committee for Therapeutics. In. TREAT\u2010NMD.eu\/resources\/TACT\/introduction\/ [Internet]. [Accessed2011Aug 31]."},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.028"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.029"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8562"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.144"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.68"},{"key":"e_1_2_12_44_2","unstructured":"US Food and Drug Administration. Guidance for industry adaptive design clinical trials for drugs and biologics. In: FDA.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. [Internet] [Accessed2011Apr 20]."},{"key":"e_1_2_12_45_2","volume-title":"Registries for evaluating patient outcomes: a user's guide","author":"Gliklich RE","year":"2010"},{"key":"e_1_2_12_46_2","unstructured":"Myasthenia Gravis Foundation of America. In: myasthenia.org [Internet] [Accessed2011Aug 31]."},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200007)48:1<11::AID-ANA4>3.0.CO;2-V"},{"key":"e_1_2_12_48_2","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non\u2010randomized control group","volume":"17","author":"D'Agostini RB","year":"1998","journal-title":"Stat Med"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1010600"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3900"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.06.017"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.23330","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.23330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:48:56Z","timestamp":1697431736000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.23330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/mus.23330"],"URL":"https:\/\/doi.org\/10.1002\/mus.23330","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]}}}